title: Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
abstract: During the periods of seasonal flu in 2003 and 2004, it was found that about 45 percent of elderly people in Japan had been inoculated with influenza vaccines. Comparatively, however, the proportion of inoculation with pneumococcal vaccine was only 0.1 percent. Taking into account such incongruent proportions, this study assesses health and economic benefits of vaccination strategies for both influenza and pneumonia particularly for the elderly population in Japan. To accomplish this objective, a cost-effectiveness analysis was conducted with the use of the Monte Carlo simulation based on the data from medical literature as well as from the public organizations, wherein three strategic patterns were delineated and compared (i) no vaccination (ii) influenza vaccine only, and (iii) combined influenza with pneumococcal vaccines. The cost for one year of life saved by each strategy was compared with the scenario of no vaccinations. It was found that for 100,000 elderly people over 65 years of age in Japan, the cost-effectiveness ratio of influenza-only vaccination was 516,332 Japanese yen per one year of life saved, while the combined vaccinations of influenza with pneumococcal was 459,874 Japanese yen for the same benefit. The incremental cost-effectiveness ratio of the strategies (iii) versus (ii) was 426,698 Japanese yen per one year of life saved for 100,000 people. Consequently it was indicated that the combined vaccinations would be more cost-effective than the vaccination for influenza only.
authors.affiliation: Department of Sociomedical Infomatics, Division of Applied Medical Statistics and Decision Sciences, Kobe University Graduate School of Medicine, Kobe, Japan. cai1972jp@yahoo.co.jp
authors.forename: Li
authors.initials: L
authors.lastname: Cai
authors.forename: Hachiro
authors.initials: H
authors.lastname: Uchiyama
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Yanagisawa
authors.forename: Isao
authors.initials: I
authors.lastname: Kamae
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003362:Cost-Benefit Analysis; D005260:Female; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007252:Influenza Vaccines / Q000191:economics*; D007251:Influenza, Human / Q000517:prevention & control*; D007564:Japan; D008297:Male; D009010:Monte Carlo Method; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics*
chemical_list: D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines